Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

The deal will integrate SDS Rx’s specialized delivery network of US locations into DHL’s Life Sciences & Healthcare division, strengthening same-day and final-mile services as demand for specialty pharma and patient-centered logistics continues to rise.

DHL Supply Chain Acquires SDS Rx, Expanding Last-Mile Healthcare Logistics

Podcasts

This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.

Pharma Pulse: White House Eyes China Drug Restrictions, Pfizer-BioNTech Vaccine Data Strong, and Samsung Biologics Secures US Deal

The South Korean CDMO has signed its second multi-billion-dollar contract in less than a year, even as shifting US trade policies and looming tariffs create challenges for global drugmakers.

Samsung Biologics Secures $1.3B US Manufacturing Deal Amidst Tariff Uncertainty

This episode of Pharma Pulse covers Florida’s plan to roll back school vaccine mandates amid a measles outbreak, President Trump’s renewed focus on limiting direct-to-consumer pharma advertising, and ICER’s latest cost-effectiveness analysis of GLP-1 obesity treatments semaglutide and tirzepatide.

Pharma Pulse: Measles Outbreak Spurs Vaccine Mandate Debate, Trump Eyes DTC Ad Restrictions, and ICER Reviews GLP-1 Costs

This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.

Pharma Pulse: Novartis Expands Cardiovascular Pipeline, Flu Severity Drivers Identified in Seniors, and Fixing Medication Nonadherence

This episode of Pharma Pulse covers the FDA’s decision to restrict bulk ingredients for compounded GLP-1 therapies, new evidence showing RSV vaccines improve cardiorespiratory outcomes in adults over 60, and pharmacy owners’ concerns over barriers to participating in the Medicaid Drug Price Negotiation Program.

Pharma Pulse: FDA Blocks Compounded GLP-1 Ingredients, RSV Vaccination Benefits Seniors, and Pharmacies Struggle With Pricing Program

By reducing waste, improving forecasting, and strengthening payer negotiations, these  technologies are helping pharmaceutical companies unlock efficiency, accelerate adoption, and differentiate in competitive markets.

Precision Dosing as a Market Strategy: How Model-Informed Tools Drive Cost, Speed and Access

This episode of Pharma Pulse covers Gilead’s groundbreaking on a new technical development hub to accelerate biopharma innovation, the World Health Organization’s decision to add GLP-1s to its Essential Medicines List for diabetes, and new data showing high-dose influenza vaccines reduce heart risks in older adults.

Pharma Pulse: Gilead Expands R&D Hub, WHO Adds GLP-1s to Essential Medicines List, and High-Dose Flu Vaccine Shows Heart Benefits

The new 180,000-square-foot facility in Foster City anchors the company’s long-term $32 billion investment in domestic manufacturing and R&D.

Gilead Breaks Ground on Technical Development Hub to Drive US Biopharma Innovation

This episode of Pharma Pulse covers President Trump’s appeal to the Supreme Court to preserve pharma tariffs, Sanofi’s 10% stock drop after Amlitelimab failed in Phase III, and new research showing how the COVID-19 pandemic reshaped pneumococcal mortality trends.

Business and Finance